BioMed Research International has retracted the article titled “The Copper Radioisotopes: A Systematic Review with Special Interest to 64Cu” [1]. The article was found to contain a substantial amount of material from the following published articles:
Szymański et al. [2], which is cited as reference [4].
Wadas et al. [3], which is cited as reference [3].
Carolyn and Ferdani [4], which is cited as reference [54].
Smith et al. [5], which is cited as reference [34].
References
- 1.Niccoli Asabella A., Cascini G. L., Altini C., Paparella D., Notaristefano A., Rubini G. The copper radioisotopes: a systematic review with special interest to 64Cu. BioMed Research International. 2014;2014:9. doi: 10.1155/2014/786463.786463 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 2.Szymański P., Fraczek T., Markowicz M., Mikiciuk-Olasik E. Development of copper based drugs, radiopharmaceuticals and medical materials. BioMetals. 2012;25(6):1089–1112. doi: 10.1007/s10534-012-9578-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Wadas T., Wong E., Weisman G., Anderson C. Copper Chelation Chemistry and its Role in Copper Radiopharmaceuticals. Current Pharmaceutical Design. 2007;13(1):3–16. doi: 10.2174/138161207779313768. [DOI] [PubMed] [Google Scholar]
- 4.Carolyn J., Ferdani R. Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical Research. Cancer Biotherapy & Radiopharmaceuticals. 2009 doi: 10.1089/cbr.2009.0674. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Smith N. A., Bowers D. L., Ehst D. A. The production, separation, and use of 67Cu for radioimmunotherapy: A review. Applied Radiation and Isotopes. 2012;70(10):2377–2383. doi: 10.1016/j.apradiso.2012.07.009. [DOI] [PubMed] [Google Scholar]